00:00:00Introduction
00:01:33First-Line Treatment
00:20:36Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy
इस एपिसोड के बारे में
अंग्रेज़ी
संयुक्त राज्य अमरीका
नोद्स दिखाएं 🔗
अनुलिपि 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
पिछले एपिसोड्स खोजें
Oncology Today with Dr Neil Love के पिछले एपिसोड खोजें।
इस पॉडकास्ट के अन्य एपिसोड
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:
Introduction (0:00)
New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
Utility …
Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
Managing brain metastases in triple-negative breast cancer (6:30)
EGFR x HER3-directed bispecific antibodies for metastatic tr…
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:
Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after c…
Featuring perspectives from Dr Sara M Tolaney, including the following topics:
Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)
First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)
First-lin…
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:
Introduction (0:00)
Minimal Residual Disease Assays in Community-Based Practice (1:24)
New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
Richter T…
अस्वीकरण: इस पृष्ठ पर एम्बेडेड पॉडकास्ट और कलाकृति Dr. Neil Love से हैं, जो इसके मालिक की संपत्ति है और Listen Notes, Inc. से संबद्ध या समर्थित नहीं है।
संपादित करें
पॉडकास्ट डेटाबेस को अपडेटेड रखने में मदद के लिए धन्यवाद।
